æ°åã³ããã¦ã¤ã«ã¹ï¼æ£å¼å称ã¯ãSARS-CoV-2ãï¼ã«ãã£ã¦å¼ãèµ·ããããçç¶ã«ã¯ããã¾ãã¾ãªãã®ããããããã¾ã§ä¸çä¸ã®ææè ããã®å ±åã«ãããããã«å ¸åçãªçç¶ãèºçã®ã»ããä¸ç¢ãå è¦ã»å³è¦é害ãè é害ããããã¨ãæããã«ãªã£ã¦ããã
ã§ã¯ããããã®çç¶ã¯ã©ããã£ãã¡ã«ããºã ã«ãã£ã¦å¼ãèµ·ããããã®ã ããããä¸çåå½ã®èª¿æ»ã«ããã¨ãæ§å¥ã年齢層ã«ãã£ã¦ææãããããç°ãªããã¦ã¤ã«ã¹ææã®éç度ãæ»äº¡çã«é常ã«åãããããã¨ãããã£ã¦ãããç·æ§ãé«é½¢è ãããã¦ç³å°¿ç ã»é«è¡å§ã»å¿ç¾æ£ãªã©ã®âæç ãã¡âãæãéçåãããããã¨ãããã£ã¦ããã
é¢é£è¨äº ï¼æ°åã³ããã¦ã¤ã«ã¹ææçã®æ»äº¡çã¯ããªããç·æ§ã®ã»ããé«ããã®ãï¼ è¦ãã¦ããçç±
æ°åã³ããã¦ã¤ã«ã¹ææçãCOVID-19ããæåã«å ±åããã¦ä»¥æ¥ãå°é家ãå¸æ°ç§å¦è ããã¯1,800ãè¶ ããæ°ã®è«æï¼æ»èªåã®ãã¬ããªã³ããå«ãï¼ãçºè¡¨ããã¦ãããããã§ã¯ãCOVID-19ã®çç¶ããã®ä»çµã¿ã«é¢ããç 究è«æãæç²ãã¦ãæããã«ãªãã¤ã¤ããã¡ã«ããºã ãç´¹ä»ãããã
1: ã©ããã£ã¦ææããã®ãï¼
ããããã¡ã®ä½ã®ä¸ã®ç´°èã«ã¯ãæ°åã³ããã¦ã¤ã«ã¹ããå¹çããä¾µå ¥ã§ããååçãªä»çµã¿ããããç´°èã¸ã®âå ¥ãå£âã¨ãã¦ä½¿ç¨ããããACE2ãå容ä½ã¨ãããã±ã質ã®åè§£é µç´ ã§ãããTMPRSS2ããFURINï¼ãã¼ãªã³ï¼ãã§ããã
ã¦ã¤ã«ã¹ã¯ã¾ãã表é¢ã«ããçªèµ·ç¶ã®ã¹ãã¤ã¯ããã±ã質ãã宿主細èã®ACE2å容ä½ã«ã´ã£ããã¨çµåããããããã¨ãç´°èèã«ããããã±ã質ã®åè§£é µç´ ãTMPRSS2ãããFURINãããã¦ã¤ã«ã¹ã®ã¹ãã¤ã¯ããã±ã質ãé©åãªä½ç½®ã§åæããã¦ã¤ã«ã¹ã¨ç´°èã®èåãå©ããã
ãããã¦ã¦ã¤ã«ã¹ã¯ç´°èå ã«ä¾µå ¥ãã¦éºä¼ç©è³ªï¼RNAï¼ãæ³¨å ¥ããããããã¡ã®ç´°èãâå·¥å ´åâãã¦ã¦ã¤ã«ã¹ã大éã«èªå·±è¤è£½ãããããããã«ãªãã®ã ã
COVID-19ã®æ£è ã®ãªãã§ãé«è¡å§ã®äººãéçåããããçç±ã®ã²ã¨ã¤ã«ãACE2ãè¡å§ã調ç¯ããããã«éè¦ãªå容ä½ã§ãããã¨ãæãããã¦ãããã¦ã¤ã«ã¹ãå ã«ä¾µå ¥ãã¦ãã¾ãã¨ããã®å½¹ç®ãæãããªããªãã®ã ã
ã¾ãTMPRSS2ã¯ç·æ§ãã«ã¢ã³ã§ããã¢ã³ããã²ã³ã®å容ä½ã§ãããããã®çºç¾éã¯ç·æ§ã«éçåããæ£è ãå¤ãåå ã¨ãªã£ã¦ããå¯è½æ§ãçããã¦ãããFURINã«ã¤ãã¦ã¯COVID-19ã«é¢é£ããç 究è«æãã¾ã å°ãªãã®ã§ããã§ã¯å²æããããFURINã¯èºçµç¹ãæ°ç®¡æ¯ã®ä¸é¨ã®ä¸ç®ç´°èã§çºç¾ãã¦ãããACE2/TMPRSS2ã®çµã¿åããã ããããæ½å¨çã«25ãã¼ã»ã³ã以ä¸ã®ç´°èãææããããããã¦ããå¯è½æ§ãããã¨ããã
ACE2ã®çºç¾éã¯ãå¹´é½¢ãæ§å¥ãã©ã¤ãã¹ã¿ã¤ã«ã«ãã£ã¦å¤ããã¨ãããç´°è表é¢ã«ããACE2å容ä½ã¯å¹´é½¢ã¨ã¨ãã«å¢å ããä¸è¬çã«å¥³æ§ãããç·æ§ã®ã»ãããã®å¯åº¦ãé«ãå¾åãããã¨å ±åããã¦ããããããã¯åãªãå¾åã«ããã¾ããããæ°åã³ããã¦ã¤ã«ã¹ã®ææè ã女æ§ããç·æ§ã«å¤ãçç±ã説æãããã¨ãã§ãã¾ããã¨ããã¤ãã®ãã¤ãã«ãã«ã¯ã«ããè¸é¨ã¯ãªããã¯ã®ãã¼ã©ã³ãã»ã¢ã¤ã«ãºææã¯ææããã
ã¾ããACE2ã®çºç¾éã¯ãéåãå«ç ã«ãã£ã¦ãä¸æãããã¨ãããã£ã¦ãããå¿ç¾æ£ãé«è¡å§ãæ ¢æ§éå¡æ§èºç¾æ£ãªã©ã®æç ãã¡ã®äººã ããèºã®ACE2çºç¾éãä¸æããã¨ããã
2: ä½ã®ã©ã®çµç¹ã«ææããã®ãï¼
çåã¨ãªãã®ã¯ãããããããããã®ä½ã®ãã©ããã§çºç¾ãã¦ãããã ãããçµè«ããè¨ãã¨ãæ°åã³ããã¦ã¤ã«ã¹ã¯ãåºæ¬çã«ACE2ã¨TMPRSS2ï¼ã¾ãã¯FURIN)ã®ä¸¡æ¹ãçºç¾ãã¦ããçµç¹ã®ä¸ç®ç´°èã«ææããå¾åã«ãããCOVID-19ã®æ£è ã®å¤ãã«çç¶ãç¾ããæ°ç®¡æ¯ãèºã¯ãããã2ã¤ã®å容ä½ãçºç¾ãã¦ããçµç¹ã®ä¸»ãªä¾ã§ããã
ACE2ã¨TMPRSS2ã®éºä¼åçºç¾ã¯ãçµç¹ç´°èã®ç¨®é¡ã«ãã£ã¦ç°ãªã£ã¦ãããããã«ã¯å人差ãæ§å·®ããããACE2ã®çºç¾ã¯ãèºãå¿èãå°è ¸ãè èã精巣ãèèã®ãç¹ã«çµç¹è¡¨é¢ã§ä¸ç®ãå½¢æããä¸ç®ç´°èã§å ±åããã¦ããã
ã¾ããGTExï¼Genotype-Tissue Expressionï¼ãã¨å¼ã°ããéºä¼åçºç¾ã®çµç¹çå·®ç°ãè¨é²ããããã¼ã¿ã»ããã«ããã¨ãå¼å¸å¨ç³»ï¼èºï¼ãæ¶åå¨ç³»ï¼çµè ¸ãå°è ¸ãªã©ï¼ã循ç°å¨ç³»ï¼å¿èãåèãªã©ï¼ãæ³å°¿å¨ç³»ï¼è èï¼ãçæ®å¨ç³»ï¼ç²¾å·£ãåµå·£ï¼ãå«ãè¤æ°ã®çµç¹ã«ããã£ã¦ãACE2ãä¸ç¨åº¦ã®ã¬ã´ã§ã«ã§åºãçºç¾ãã¦ãããã¨ãããã£ã¦ãããTMPRSS2ãèºãè èãå°è ¸ã精巣ãªã©ã®çµç¹ã§å¹ åºãçºç¾ãã¦ããã
3: ã»ãã«ã©ããªçç¶ãç¾ããï¼
ã»è
¸ï¼ä¸ç¢ãååãªã©ï¼è»½çï¼
ACE2ã¨TMPRSS2ã®å°è
¸ã§ã®é«ãéºä¼åçºç¾éãããCOVID-19ã¯æ¶åå¨ç³»ï¼ä¸ç¢ãªã©ï¼ã®çç¶ãä¿ããã¨ã示åããã¦ããã
å®éã«æ¦æ¼¢ã§å®æ½ããã調æ»ã«ããã¨ãæ¯è¼ç軽çã§æ¸ãã æ£è ã®å¤ããæåã«æããçç¶ã¨ãã¦ãä¸ç¢ããæãã¦ããã206人ã®è»½çæ£è ã®ãã¡ã19.4ãã¼ã»ã³ãã¯ä¸ç¢ãæåã®çç¶ã§ãå ¨ä½ã®57ãã¼ã»ã³ãã«æ¶åå¨ç³»ã®çç¶ããã£ãããããã¯å¹³åãã¦5.4æ¥ç¶ããã¨ããã
ã¾ãå¥ã®èª¿æ»ã«ããã¨ãæ°åã³ããã¦ã¤ã«ã¹ææçã®æ£è 204人ã®ãã¡ãè ¹çãä¸ç¢ãååãªã©ã18.6ãã¼ã»ã³ãã®æ£è ãæ¶åå¨å®ã«é¢ããçç¶ãçµé¨ãã¦ãããæ¶åå¨çç¶ã®ãã£ãæ£è ã§ã¯ãçç¶ã®ãªãæ£è ã«æ¯ã¹ã¦èé µç´ å¤ãé«ããåçæ°ãå°ãªããããããã³ãã³æéï¼è¡æ¶²ã®ååºç°å¸¸ï¼ãé·ãã£ããã¨ãå ±åããã¦ããã
ã»é¼»ï¼å
è¦ã»å³è¦ç°å¸¸ï¼è»½çï¼
æ°åã³ããã¦ã¤ã«ã¹ææçã®åæçç¶ãç¹ã«40æ³ä»¥ä¸ã®äººã
ã«ã¯å
è¦ç°å¸¸ã¨å³è¦ç°å¸¸ãå ±åããã¦ãããéå½ã§ã¯30ãã¼ã»ã³ãããã¤ãã§ã¯67ãã¼ã»ã³ãï¼3人ä¸2人ï¼ã¨ããããªãã®å²åã®COVID-19æ£è
ããå
è¦ã»å³è¦é害ãå ±åãã¦ããã
ãã¤ã³ãã¯ã鼻詰ã¾ãã®çç¶ã§ã¯ãªãã¦ããã«ãããå³è¦ãèãããã¾ã£ããæããããªããªã£ãããããã¨ã ãå è¦ã»å³è¦ç°å¸¸ã®æ£è ã¯ç·æ§ããã女æ§ã«ããå¤ããCOVID-19ã®çç¶èªä½ãæ¯è¼ç軽çã§æ¸ããã¨ãããã£ã¦ããã
ã«ãªãã©ã«ãã¢å¤§å¦ãµã³ãã£ã¨ã´æ ¡ã®èª¿æ»ã«ããã¨ãå è¦ãå³è¦ã®åªå¤±ã®å¤ãã¯è»½åº¦ã§ã¯ãªããã¾ã£ããæããããªããªãæ·±å»ãªãã®ã ã¨ãã¦ããããããå復çã¯é«ããææå¾2ï½4é±é以å ã«å è¦ã¨å³è¦ãå復ãããã¨ãå ±åããã¦ããã
ã«ãªãã©ã«ãã¢å¤§å¦ãµã³ãã£ã¨ã´æ ¡ã®ç 究ã§ã¯æ°åã³ããã¦ã¤ã«ã¹ã®é½æ§ã¨è¨ºæããã人ãã¡ã¯ãé°æ§ã¨è¨ºæããã人ã ãããå è¦ã»å³è¦ç°å¸¸ãå ±åããå¯è½æ§ã10å以ä¸ã ã¨çºè¡¨ãã¦ããããã®ãã¨ãããå è¦ã»å³è¦ç°å¸¸ã¯æ°åã³ããã¦ã¤ã«ã¹ã®é½æ§è¨ºæã«ããã¦ä¿¡é ¼æ§ã®é«ãäºæ¸¬å åã§ãããã¨ã示åããã¦ããã
ã«ãããè³ã«ä¼ããå ç´°èã«ã¯ãACE2ã¨TMPRSS2éºä¼åã¯çºç¾ãã¦ããªãããã®ããå è¦ã»å³è¦ç°å¸¸ã®ã¡ã«ããºã ã¯ãããã¾ã§ã¯ä¸æã ã£ããããããæ°ããªå ±åã§ã¯ãå ç´°èã®å¨ãã«ããå è¦ä¸ç®ã®æ¯æç´°èã幹細èã¯ãé¼»å¼å¸å¨ä¸ç®ã®ç´°èã¨åæ§ã«ããããã®éºä¼åã®ä¸¡æ¹ãçºç¾ãã¦ãããã¨ãããã£ãããã®ç¥è¦ã¯æ°åã³ããã¦ã¤ã«ã¹ã¸ã®ææãå è¦ã»å³è¦ç°å¸¸ãå¼ãèµ·ããã¡ã«ããºã ã示ããã®ã§ããã
ã»è
èï¼è
é害ï¼éçï¼
è
èã¯ACE2ã¨TMPRSS2ã®çºç¾éãå¤ããå¼å¸å¨ç³»ä»¥å¤ã§æ°åã³ããã¦ã¤ã«ã¹ãè
èãªã©ã®èå¨ã«ç´æ¥ææãããã©ããã¯ããã¾ã®ã¨ããä¸æã§ãããããããæ¦æ¼¢ã®ç
é¢ã§1æ17æ¥ãã3æ3æ¥ã¾ã§ã«å
¥é¢ãã¦ããCOVID-19ã®æ£è
85åã®ãã¡ã23åï¼27.6ãã¼ã»ã³ãï¼ã®æ£è
ãæ¥æ§è
ä¸å
¨ãèµ·ããã¦ãããã¨ãå ±åããã¦ããã
ã¾ãããã®ãã¡6åã®æ»å¾ã®è èçµç¹ã調ã¹ãã¨ãããé度ã®æ¥æ§å°¿ç´°ç®¡å£æ»ã¨ææã示ããªã³ãç浸潤ãèªãããããããã«ãè èå ã«ã¯ã¦ã¤ã«ã¹æ§ç²åãèªããããè 尿細管ã«ã¯æ ¸ããã±ã質ï¼NPï¼æåãèç©ãã¦ãããã¨ã確èªãããã¨ããã
å¥ã®èª¿æ»ã§ã¯ãCOVID-19ã®æ£è ã«ã®å¤ãã«è æ©è½é害ãã¿ããããã®ãã¡ããä¸é¨ã«æ¥æ§è é害ãçºçããããã®ç 究ããã¯COVID-19ã®éçæ»äº¡æ£è ã¨ãèç½å°¿ãè¡å°¿ãè¡ä¸å°¿ç´ çªç´ ãè¡æ¸ ã¯ã¬ã¢ããã³ãå°¿é ¸ãDãã¤ãã¼ã®ä¸æãææã«é¢é£ãããã¨ã示ããã¦ããããã®ãã¨ãããè æ©è½é害ã®ãã¼ã«ã¼ã¯é¢å æ»äº¡ãªã¹ã¯ã¨é¢é£ãããããæ£è ã®è æ©è½ã®ã¢ãã¿ãªã³ã°ã¯ååãªæ³¨æãå¿ è¦ã§ãããã¨ã示åããã¦ããã
4: éçåããæ£è ã®ç¹å¾´ã¯ï¼
æ°åã³ããã¦ã¤ã«ã¹ã®ææãåºããã«ã¤ããé«ãªã¹ã¯è ãç¹å®ããããã®ãã¼ã«ã¼ã®éçºãæ¥ããã¦ãããæåã®éæºå°ã¨ãªã£ãä¸å½ãããã¦ãã¾ã®ã¨ããä¸çã§æãæ»äº¡çã®é«ãã¤ã¿ãªã¢ï¼12.97ãã¼ã»ã³ããã¸ã§ã³ãºã»ãããã³ãºå¤§å¦èª¿ã¹ï¼ã§æããã«ãªã£ã¦ããéçåã®å¾åã¯ãç·æ§ãé«é½¢è ãæç ãã¡ï¼é«è¡å§ãå¿ç¾æ£ãç³å°¿ç ããããããªã©ï¼ã ã£ãã
ã»è¥è
ãå«ãè¥æºã®äººãã¡
ã¨ããããè±å½ã¨ç±³å½ã§ã®ææãåºã¾ã£ã¦ãããã¡ã«ãæ¯è¼çè¥ãæ£è
ã®éçåãå ±åãããããã«ãªã£ã¦ããã両å½ã®å»å¸«ãã¡ã«ããã¨ãéä¸æ²»ç室ï¼ICUï¼ã«éã°ããæ£è
ã¯ããã¦ãè¥æºã®ç·æ§ã ã¨ããã
ããã¾ã§ã®ç 究ã§ã¯ãè¥æºã¯ç³å°¿ç ãé«è¡å§ãå¿ç¾æ£ãªã©ã®ç æ°ãä½µçºãããããã¨ãããã£ã¦ãããä¸çåå½ã®è¥æºçãè¦ãã¨ãä¸å½ã¯6.2ãã¼ã»ã³ããã¤ã¿ãªã¢ã¯19.9ãã¼ã»ã³ããè±å½ã¯27.8ãã¼ã»ã³ããç±³å½ã¯36.2ãã¼ã»ã³ãã¨ãªã£ã¦ãããã¡ãªã¿ã«æ¥æ¬ã®è¥æºçã¯4.3ãã¼ã»ã³ãã§ããã
è±å½ã®å¤§å¦ã®èª¿ã¹ã«ããã¨ã73ãã¼ã»ã³ãã®ï¼éä¸æ²»ç室ã«éã°ããï¼éçåæ£è ã¯ç·æ§ã§ã73.4ãã¼ã»ã³ããè¥æºã ã£ãã¨ä¼ãããã¦ãããã¾ãä¸é¨å ±éã«ããã¨ã人工å¼å¸å¨ãä»ãã¦ãã50æ³æªæºã®æ£è ã®90ãã¼ã»ã³ãã¯è¥æºãã ã¨ããããã®æ§å·®ã¨BMIï¼ä½æ ¼ææ°ï¼ã¯ç¹çãã¹ããã®ã ã
ããã®ã¦ã¤ã«ã¹ã¯æããããã®ã§ãè¥è ãç¹ã«è¥æºã®è¥è ã襲ãå¯è½æ§ãããã¾ãã太ãããã®äººã¯æ¬å½ã«æ³¨æããå¿ è¦ãããã¾ããã¨ããã©ã³ã¹ã®å ç«å¦è ã¸ã£ã³ï¼ãã©ã³ã½ã¯ã»ãã«ãã©ãã·ã¼ææã¯è¨ãããè¥æºã®åé¡ãããç¥ããã¦ããç±³å½ãå¿é ã§ããããããè¥æºã®ããã§æã大ããªåé¡ãæ±ãããã¨ã«ãªãã§ãããããã
å対ã«ä¸ççãªå¾åã¨ãã¦ãæç ããããªã65æ³ä»¥ä¸ã®äººã ã¯ãç·å¥³ã¨ãã«ææãã¦ãæ»äº¡ãªã¹ã¯ã¯é常ã«å°ãããã¨ãå ±åããã¦ããã
ã»ç·æ§
ACE2ã¨TMPRSS2ã®éºä¼åçºç¾ã¬ã´ã§ã«ã¨éçåã®é¢é£ã«ã¤ãã¦ã¤ã¿ãªã¢ã§å®æ½ããã調æ»ã§ã¯ãã¤ã¿ãªã¢äººéå£ã«ããã¦ACE2ã®çºç¾éã¯ãæ§å¥å·®ãéçåã¨æ確ãªé¢é£ã¯ã¿ãããªãã£ãã¨ãããã¨ãããç·æ§ãã«ã¢ã³ã§ããã¢ã³ããã²ã³ã®å容ä½ã§ãããTMPRSS2ã®çºç¾éã¨ãã®éºä¼åå¤ç°ã¯ãCOVID-19ã®éçåã«å¯ä¸ãã¦ããã¨çºè¡¨ããã¦ãããããã¯ç·æ§ã«éçåæ£è
ãå¤ãçç±ã®ã²ã¨ã¤ã«ãªãå¯è½æ§ãããããªããã¢ã³ããã²ã³ã¯ãç·å¥³ã¨ãã«çèã骨ãè¡ç®¡ãè³ãçæ®å¨ãªã©ã«å¹
åºãä½ç¨ããã
ã»åã©ãã¯çç¶ã軽ã
ä¸å½ã§ã®å ±åã¨åãããã«ãç±³å½ã§ã18æ³ä»¥ä¸ã®åã©ãã¯æ°åã³ããã¦ã¤ã«ã¹ææçã«ããã¦ã大人ãããã¯ããã«è»½çã§ãããã¨ãå ±åããã¦ãããåã©ããã¡ã®çç¶ã¯è»½ãã ãã§ãªããå®éã«COVID-19ã§ããã¨è¨ºæãããå¯è½æ§ãä½ãã2æ12æ¥ãã4æ2æ¥ã¾ã§ã®è¨é²ã«ããã¨ã18æ³æªæºã®åã©ããã¡ã¯ç±³å½ã®äººå£ã®22ãã¼ã»ã³ããå ããã«ãããããããCOVID-19ã®æ£è
ã¯ããã1.7ãã¼ã»ã³ãã ã£ãã
ã強調ãããã®ã¯ããã®ç æ°ã«ããã£ã¦ããåã©ããã¡ã®ãªãã«ã¯ãç¡çç¶ã§é常ã«è»½ãçç¶ã®ããåã©ããã¡ã大å¢ããã¨ãããã¨ã§ããã¨ããã¥ã¼ã¨ã¼ã¯å·ã°ãã¼ãã«ãã«ã¹ã®ãã£ã¬ã¯ã¿ã¼ã§ããã¨ãªãã¯ã»ããå士ã¯è¨ããããã®å¹´é½¢å±¤ã®æ»äº¡ãªã¹ã¯ã¯é«ããªãã®ã¯ç¢ºãã§ããããã人ã ã«ç¥ã£ã¦ã»ããã®ã§ãã
ããããåã©ããè¥è ã§ãéçã«ãªãã±ã¼ã¹ããªãããã§ã¯ãªãããã®å ´åããããããå¿èç ãå ç«åã®ä½ä¸ï¼ä¾ãã°ãããæ²»çãªã©ï¼ã¨ãã£ãåºç¤ç¾æ£ã®ããæ£è ãã»ã¨ãã©ã ã¨ããã
ãåºç¤ç¾æ£ã®ãªãå¥åº·ãªåã©ãã®éçåã¯ãããããã»ãã®åã©ããã¡ãããã¦ã¤ã«ã¹ã«å¯¾ããéå°ãªççåå¿ããããã£ã¦ããå¯è½æ§ãããã¾ãããã®ãããªéºä¼çç´ å ããã¡ãããã¦ããã®ããããã¾ãããã¨ããã¥ã¼ã¨ã¼ã¯å·ãã¤ããã¼ã¯ã®ã³ã¼ã¨ã³å»çã»ã³ã¿ã¼ã§å°å ææçãå°éã¨ãããã¼ãªã¼ã»ã«ã¼ãã³å士ã¯æ¨æ¸¬ããã
å®éããµã¤ãã«ã¤ã³ã¹ãã¼ã ã¨ãã¦ç¥ãããå±éºãªå ç«éå°åå¿ãããã¤ã¦å¤ãã®SARSæ£è ã®æ»ãå¼ãèµ·ããããããã¯è¥ãCOVID-19æ£è ã®æ»äº¡ä¾ã«ãé¢ä¸ãã¦ããã¨èãããã¦ããã
5: å ç«ã·ã¹ãã ã®æ´èµ°ããµã¤ãã«ã¤ã³ã¹ãã¼ã ãã¯ããªãèµ·ããï¼
COVID-19ã®çºçããæ²»çã«ã¯ãå¥å¦ãªãã¿ã¼ã³ããããã¾ãæ£è ã¯æåã®1é±éã»ã©ãããã®çç¶ãã²ã©ã人ãªãã¤ã³ãã«ã¨ã³ã¶ã®ãããªçç¶ãçµé¨ãããããã¦ã ããã7æ¥ç®ã«ã¯ããããã®æ£è ã¯å°ãã ãçç¶ããã·ã«ãªã£ãã¨æããããã ã
ã¨ãããã軽çã¨éçåã®ææãåãããã®ã7ï½10æ¥ç®ã§ããã軽çã®æ£è ã¯ãã®ã¾ã¾å¿«æ¹ã«åããããéçåããæ£è ã¯å°ãã ãæ°åããããªã£ããã¨ãçªç¶æªåããããµã¤ãã«ã¤ã³ã¹ãã¼ã ãèµ·ããã®ã ã
ãµã¤ãã«ã¤ã³ã¨ã¯ãããããã¡ã®å ç«ã·ã¹ãã ãç åä½ã¨æ¦ãéã«æ¾åºãããããã±ã質ã®ãã¨ã§ãç´°èãç åä½ããæ»æãåããã¨ãµã¤ãã«ã¤ã³ã·ã°ãã«ãåºãã¦å ç«ç´°èãå¼ã³åºããã¨ãããããã®ãµã¤ãã«ã¤ã³ã¯ã¨ãã«1ã«æã§éå°ã«æ´»æ§åãããå¶å¾¡ã§ããªãã¬ã´ã§ã«ã®ãµã¤ãã«ã¤ã³ãåµã®ããã«æ¾åºããããã¨ãããã¨ããããããããµã¤ãã«ã¤ã³ã¹ãã¼ã ãã¨å¼ã¶ã
COVID-19ã®éçåã¯ãã¦ã¤ã«ã¹èªèº«ãåå ã¨ããããã§ã¯ãªããèªå·±å ç«ã«ãããµã¤ãã«ã¤ã³ã¹ãã¼ã ãèºãã¯ããã¨ããè¤æ°ã®èå¨ã§ççãå¼ãèµ·ãããæ£è èªèº«ãæ»ã«è³ããããã¨èãããã¦ãããå ç«ã·ã¹ãã ã®æ´èµ°ããé ¸ç´ ä¸è¶³ã¨åºç¯å²ã«åã¶ççã¯ãè èãèèãå¿èãè³ããã®ä»ã®èå¨ã«ããã¡ã¼ã¸ãä¸ããã®ã ã
ãã¾ã®ã¨ãããCOVID-19ã¯éçåããå¯è½æ§ãSARSãããä½ãããéçåã®éç¨ã¯ããä¼¼ã¦ããã¨ããããã®ããæç ã®ãªãå¥åº·ãªè¥è ããæ¥æ§å¼å¸çª®è¿«çå群ï¼ARDSï¼ã§äº¡ããªãçç±ã¯ãèªèº«ã®å ç«æ»æã«ãããµã¤ãã«ã¤ã³ã¹ãã¼ã ã®çµæã§çãããã¨ãå¤ãã¨èãããã¦ããã
6: éçåãçµé¨ããæ£è ã®äºå¾ã¯ã©ããªãï¼
æ°åã³ããã¦ã¤ã«ã¹ã¯ã¾ã£ããæ°ããç åä½ã§ãããã¨ãããå ç«ããã¤äººãã»ã¼ã¼ãã ã£ãããã®ãããã®ã¦ã¤ã«ã¹ã¯ç½å®³ã®ããã«ãå°çä¸ã®äººéãã¹ã¦ã«çããææãããããããæ°åã³ããã¦ã¤ã«ã¹ææçã«ããéçåãæ»äº¡è ã«ã¯ãããã§ã¾ã¨ãããããããªåãããããã¨ãæããã«ãªã£ã¦ããã
ãã¾ã ã«ä¸æãªç¹ã¯ãéçåã«ãã£ã¦ãã¡ã¼ã¸ãåããèå¨ã¯ãããå®å ¨ã«å復ããã®ããã¨ããç¹ã ãããè¥ãã¦å¥åº·ã ã£ã人ã ããé度ã®èºçã«å ãã¦ã»ãã®èå¨ã®ççãçµé¨ãããã¨ã«ã¯ãä½ããã®é害ãæ®ããªãã¨ãéããªãã
ä¾ãã°ã軽çã§ãèºãã¯ããã¨ããèå¨ã«ä½ããã®ççããã£ãã¢ã¹ãªã¼ããã¡ã¯ã100ãã¼ã»ã³ãã®æä¹ åãçåãåãæ»ããã¨ãã§ããã®ã ããããèºçã§å ¥é¢ãã人ã¯ãéé¢å¾ã®1å¹´éã¯ãåå¹´é½¢ã®å¯¾ç §ç¾¤ã¨æ¯ã¹ã¦ç´4åã®å¿èç ãªã¹ã¯ãããããã®å¾ã®9å¹´éã¯ããããç´1.5åã®ãªã¹ã¯ãããã¨ã®ç 究ããããCOVID-19ã¯ããããã£ãåé¡ã®å¤§å¹ ãªå¢å ãä¿ãå¯è½æ§ãããã®ã ã
æ°åã³ããã¦ã¤ã«ã¹ã®é¢é£è¨äº
âç¥ã£ã¦ããã¹ãåºç¤ç¥è
ææããã¨ãã®ããã«ç¥ã£ã¦ããã¹ãã6ã¤ã®ãã¨ã
ã¯ã¯ãã³ã¯ããã¤ã§ããï¼ åºç¤ããææ°äºä¾ã¾ã§ãç¥ã£ã¦ããã¹ããã¨ã
ãã¹ã¯ã¯å½¹ã«ç«ããªãï¼ ã¯ã¯ãã³ãå±ãæ¥ã¯è¿ãï¼ ã8ã¤ã®é¢¨èª¬ãã®çå½
ã¹ãã¼ããã©ã³ããã¼ãã¼ããæ£ããé¤èããæ¹æ³âããããä½ãèµ·ããã®ãï¼
æ°åã¦ã¤ã«ã¹ã®æææ¡å¤§ã¯ãä»å¾ã©ããªçµæ«ãè¿ããã®ãï¼ èããããã3ã¤ã®ã·ããªãªãâãã¾èµ·ãã¦ãããã¨
éè¦ççºã§çç£ã追ãä»ããªããã¹ã¯ã¡ã¼ã«ã¼ã®å¤§æ··ä¹±
æ°åã¦ã¤ã«ã¹ã®ä¸ççæµè¡ã«ãã£ã¦ããæ¡æã®ç¿æ £ããæ¶ãã¤ã¤ãã
ãã¹ã¯ãé²è·æã足ããªãï¼ çµ¶ææããæ¼ãç±³å½ã®å»çç¾å ´ã®ãã¾
æææºã¯ãæ¬å½ã«ãå¸å ´ã®ããããªã®ãï¼ æ°ããªè«æãå·¡ãæ³¢ç´ææ°æ å ±ã¯å ¬å¼Twitterããã©ãã¼
TEXT BY SANAE AKIYAMA